Miromatrix Medical Inc.

2023 Q4 Form 10-Q Financial Statement

#000155837023019009 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.06M
YoY Change -49.08%
Cash & Equivalents $6.116M
Short-Term Investments $9.950M
Other Short-Term Assets $1.040M
YoY Change -10.4%
Inventory
Prepaid Expenses
Receivables $11.18K
Other Receivables
Total Short-Term Assets $17.19M
YoY Change -47.64%
LONG-TERM ASSETS
Property, Plant & Equipment $4.711M
YoY Change -19.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change -100.0%
Total Long-Term Assets $6.229M
YoY Change -19.86%
TOTAL ASSETS
Total Short-Term Assets $17.19M
Total Long-Term Assets $6.229M
Total Assets $23.42M
YoY Change -42.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.048M
YoY Change -9.44%
Accrued Expenses $2.624M
YoY Change 64.76%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $20.00K
YoY Change 29.73%
Total Short-Term Liabilities $4.966M
YoY Change 22.37%
LONG-TERM LIABILITIES
Long-Term Debt $386.0K
YoY Change 0.0%
Other Long-Term Liabilities $2.530M
YoY Change -25.67%
Total Long-Term Liabilities $386.0K
YoY Change 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.966M
Total Long-Term Liabilities $386.0K
Total Liabilities $7.879M
YoY Change 0.18%
SHAREHOLDERS EQUITY
Retained Earnings -$124.5M
YoY Change 28.26%
Common Stock $140.0M
YoY Change 7.87%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $15.54M
YoY Change
Total Liabilities & Shareholders Equity $23.42M
YoY Change -42.32%

Cashflow Statement

Concept 2023 Q4 2023 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2023#LicenseMember
CY2022Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2023#LicenseMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2023#LicenseMember
CY2023Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2023#LicenseMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2023#LicenseMember
CY2022Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2023#LicenseMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2023#LicenseMember
CY2023Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2023#LicenseMember
dei Entity Central Index Key
EntityCentralIndexKey
0001527096
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet
CY2022Q4 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet
CY2023Q3 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityNoncurrent
CY2023Q3 us-gaap Finance Lease Liability Statement Of Financial Position Extensible List
FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#FinanceLeaseLiabilityCurrent http://fasb.org/us-gaap/2023#FinanceLeaseLiabilityNoncurrent
us-gaap Substantial Doubt About Going Concern Within One Year
SubstantialDoubtAboutGoingConcernWithinOneYear
true
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40518
dei Entity Registrant Name
EntityRegistrantName
Miromatrix Medical Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-1285782
dei Entity Address Address Line1
EntityAddressAddressLine1
6455 Flying Cloud Drive, Suite 107
dei Entity Address City Or Town
EntityAddressCityOrTown
Eden Prairie
dei Entity Address State Or Province
EntityAddressStateOrProvince
MN
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
55344
dei City Area Code
CityAreaCode
952
dei Local Phone Number
LocalPhoneNumber
942-6000
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
MIRO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27419228
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6116084
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5208005
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
800100
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
800100
CY2023Q3 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
9945715
CY2022Q4 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
19989489
CY2023Q3 us-gaap Grants Receivable Current
GrantsReceivableCurrent
70000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
11176
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
930355
CY2023Q3 us-gaap Interest Receivable
InterestReceivable
9433
CY2022Q4 us-gaap Interest Receivable
InterestReceivable
107861
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
239922
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
274952
CY2023Q3 us-gaap Assets Current
AssetsCurrent
17192430
CY2022Q4 us-gaap Assets Current
AssetsCurrent
27310762
CY2022Q4 miro Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
232899
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1517956
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1673575
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4710763
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5545694
CY2023Q3 us-gaap Assets
Assets
23421149
CY2022Q4 us-gaap Assets
Assets
34762930
CY2023Q3 miro Deferred Royalties Current
DeferredRoyaltiesCurrent
862609
CY2022Q4 miro Deferred Royalties Current
DeferredRoyaltiesCurrent
979167
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1048364
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1584929
CY2023Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
17281
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
44157
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
413650
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
389649
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2624031
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1948376
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4965935
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4946278
CY2022Q4 miro Deferred Royalties Noncurrent
DeferredRoyaltiesNoncurrent
491733
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
385997
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
385997
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
11689
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2406066
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2720781
CY2023Q3 miro Interest Payable Noncurrent
InterestPayableNoncurrent
120780
CY2022Q4 miro Interest Payable Noncurrent
InterestPayableNoncurrent
99048
CY2023Q3 us-gaap Liabilities
Liabilities
7878778
CY2022Q4 us-gaap Liabilities
Liabilities
8655526
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7756284
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
190000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
190000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27419228
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20944109
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
274
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
209
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
140018271
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
130119106
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-124476174
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-104011911
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
15542371
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
26107404
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23421149
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
34762930
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11176
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12395
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27674
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
23115
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
125000
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
125000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
375000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
375000
CY2023Q3 us-gaap Gross Profit
GrossProfit
-113824
CY2022Q3 us-gaap Gross Profit
GrossProfit
-112605
us-gaap Gross Profit
GrossProfit
-347326
us-gaap Gross Profit
GrossProfit
-351885
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3506054
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4574534
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11519395
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13569434
CY2023Q3 miro Regulatory And Clinical Expense
RegulatoryAndClinicalExpense
455313
CY2022Q3 miro Regulatory And Clinical Expense
RegulatoryAndClinicalExpense
381903
miro Regulatory And Clinical Expense
RegulatoryAndClinicalExpense
1259077
miro Regulatory And Clinical Expense
RegulatoryAndClinicalExpense
1156535
CY2023Q3 miro Quality Expense
QualityExpense
416476
CY2022Q3 miro Quality Expense
QualityExpense
634511
miro Quality Expense
QualityExpense
1515394
miro Quality Expense
QualityExpense
1592778
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2143421
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2052731
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6781337
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6513748
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
6521264
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
7643679
us-gaap Operating Expenses
OperatingExpenses
21075203
us-gaap Operating Expenses
OperatingExpenses
22832495
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6635088
us-gaap Operating Income Loss
OperatingIncomeLoss
-21422529
us-gaap Operating Income Loss
OperatingIncomeLoss
-23184380
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
196681
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
143555
us-gaap Investment Income Interest
InvestmentIncomeInterest
464820
us-gaap Investment Income Interest
InvestmentIncomeInterest
205403
CY2023Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
15284
CY2022Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
15325
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
33697
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
35015
us-gaap Government Assistance Amount
GovernmentAssistanceAmount
527143
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
181397
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
128230
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
958266
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
170388
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-6453691
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7628054
us-gaap Net Income Loss
NetIncomeLoss
-20464263
us-gaap Net Income Loss
NetIncomeLoss
-23013992
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.80
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.80
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.11
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27313881
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27313881
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20895513
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20895513
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25714215
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25714215
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20664494
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20664494
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
21548250
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
322812
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
62500
CY2023Q3 miro Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
62500
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-6453691
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
15542371
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
40011298
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
252759
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
106788
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7628054
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
32742791
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
26107404
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
933422
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
62500
miro Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
62500
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8855437
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
14629
us-gaap Net Income Loss
NetIncomeLoss
-20464263
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
15542371
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
54125884
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
853130
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
363671
miro Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
414098
us-gaap Net Income Loss
NetIncomeLoss
-23013992
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
32742791
us-gaap Profit Loss
ProfitLoss
-20464263
us-gaap Profit Loss
ProfitLoss
-23013992
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
867466
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
817792
us-gaap Share Based Compensation
ShareBasedCompensation
933422
us-gaap Share Based Compensation
ShareBasedCompensation
853130
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-758
miro Non Cash Interest Income
NonCashInterestIncome
-98428
miro Non Cash Interest Income
NonCashInterestIncome
121287
miro Investment Income Net Amortization Of Discount And Premium Total
InvestmentIncomeNetAmortizationOfDiscountAndPremiumTotal
213492
miro Investment Income Net Amortization Of Discount And Premium Total
InvestmentIncomeNetAmortizationOfDiscountAndPremiumTotal
-23038
miro Deferred Offering Costs Write Off
DeferredOfferingCostsWriteOff
221254
miro Government Assistance Amount Cash Flow Impact
GovernmentAssistanceAmountCashFlowImpact
70000
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-919179
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-5424
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-35030
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-90258
miro Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-155619
miro Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
3120774
miro Increase Decrease In Tenant Improvement Allowance Receivable
IncreaseDecreaseInTenantImprovementAllowanceReceivable
-1256950
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-469201
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-640792
miro Increase Decrease In Interest Payable Noncurrent
IncreaseDecreaseInInterestPayableNoncurrent
21732
miro Increase Decrease In Interest Payable Noncurrent
IncreaseDecreaseInInterestPayableNoncurrent
20502
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-290714
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
3201641
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18255540
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20627352
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
9742734
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
26026125
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
20000000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
32535
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
856062
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
10224731
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-26882187
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
318432
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
38565
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
40612
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
182899
miro Proceeds From Issuance Of Common Stock Net
ProceedsFromIssuanceOfCommonStockNet
8867082
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
14629
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
62500
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
414098
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
62500
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
363671
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8938888
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
235826
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
908079
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-47273713
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6008105
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53611631
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6916184
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6337918
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6116084
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5537818
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
800100
CY2022Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
800100
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6916184
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6337918
us-gaap Interest Paid Net
InterestPaidNet
11965
us-gaap Interest Paid Net
InterestPaidNet
14513
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
186791
miro Noncash Investing And Financing Financing Expenses
NoncashInvestingAndFinancingFinancingExpenses
50000
miro Leased Assets Obtained In Exchange For New Operating Lease Liabilities
LeasedAssetsObtainedInExchangeForNewOperatingLeaseLiabilities
1986172
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:none;">Reclassifications</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain reclassifications to previously reported financial information on the Condensed Balance Sheets and Condensed Statements of Operations have been made to conform to the current period presentation.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:none;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
us-gaap Government Assistance Amount
GovernmentAssistanceAmount
527143
us-gaap Property Plant And Equipment Impairment
PropertyPlantAndEquipmentImpairment
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Impairment of Long-Lived Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates its long-lived assets, which consist of property and equipment and right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. No impairment charges were recorded for the three or nine months ended September 30, 2023 or 2022.</p>
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-124500000
CY2023Q3 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
9945715
CY2023Q3 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
7615
CY2023Q3 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
9938100
CY2022Q4 miro Accrued Key Opinion Leader Compensation Current
AccruedKeyOpinionLeaderCompensationCurrent
18700
CY2022Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
3422
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
140748
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
97811
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2624031
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1948376
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7425085
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7392550
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2714322
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1846856
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4710763
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5545694
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
288099
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
281285
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
867466
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
817792
CY2023Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1966953
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1434675
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
286510
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
80794
CY2023Q3 miro Accrued Research And Development Consulting Current
AccruedResearchAndDevelopmentConsultingCurrent
136500
CY2023Q3 miro Accrued Pre Clinical Study Costs Current
AccruedPreClinicalStudyCostsCurrent
50000
CY2022Q4 miro Accrued Pre Clinical Study Costs Current
AccruedPreClinicalStudyCostsCurrent
200000
CY2023Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
32820
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
112974
CY2023Q3 miro Accrued Key Opinion Leader Compensation Current
AccruedKeyOpinionLeaderCompensationCurrent
10500
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo
385997
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
385997
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
385997
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
190000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
190000000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q3 miro Number Of Votes For Common Stock Holders
NumberOfVotesForCommonStockHolders
1
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27419228
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27419228
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20944109
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20944109
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3831686
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.12
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
471000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.91
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
50000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.25
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
352000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.12
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3900686
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.01
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2827561
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.99
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.13
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.42
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
599191
CY2022Q4 miro Warrants Outstanding Weighted Average Exercise Price
WarrantsOutstandingWeightedAverageExercisePrice
6.16
miro Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
50000
miro Warrants Exercised Weighted Average Exercise Price
WarrantsExercisedWeightedAverageExercisePrice
1.25
miro Class Of Warrant Or Right Terminated
ClassOfWarrantOrRightTerminated
73191
miro Warrants Expired Weighted Average Exercise Price
WarrantsExpiredWeightedAverageExercisePrice
2.00
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
476000
CY2023Q3 miro Warrants Outstanding Weighted Average Exercise Price
WarrantsOutstandingWeightedAverageExercisePrice
7.32
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1517956
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1673575
CY2023Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
52886
CY2022Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
81325
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
413650
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
389649
CY2023Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
17281
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
44157
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2406066
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2720781
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
11689
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
82886
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
82886
CY2023Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
9480
CY2022Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
9480
CY2023Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
411
CY2022Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1299
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
56145
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
55165
us-gaap Operating Lease Cost
OperatingLeaseCost
248657
us-gaap Operating Lease Cost
OperatingLeaseCost
246455
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
28439
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
28439
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1882
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
4242
us-gaap Variable Lease Cost
VariableLeaseCost
152390
us-gaap Variable Lease Cost
VariableLeaseCost
151484
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
127917
CY2023Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
5850
CY2023Q3 miro Lessee Finance And Operating Leases Liability Payments Remainder Of Fiscal Year
LesseeFinanceAndOperatingLeasesLiabilityPaymentsRemainderOfFiscalYear
133767
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
527020
CY2023Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
12030
CY2023Q3 miro Lessee Finance And Operating Leases Liability Payments Due Next Twelve Months
LesseeFinanceAndOperatingLeasesLiabilityPaymentsDueNextTwelveMonths
539050
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
542830
CY2023Q3 miro Lessee Finance And Operating Leases Liability Payments Due Year Two
LesseeFinanceAndOperatingLeasesLiabilityPaymentsDueYearTwo
542830
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
559115
CY2023Q3 miro Lessee Finance And Operating Leases Liability Payments Due Year Three
LesseeFinanceAndOperatingLeasesLiabilityPaymentsDueYearThree
559115
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
575889
CY2023Q3 miro Lessee Finance And Operating Leases Liability Payments Due Year Four
LesseeFinanceAndOperatingLeasesLiabilityPaymentsDueYearFour
575889
CY2023Q3 miro Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
847731
CY2023Q3 miro Lessee Finance And Operating Leases Liability Payments Due After Year Four
LesseeFinanceAndOperatingLeasesLiabilityPaymentsDueAfterYearFour
847731
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3180502
CY2023Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
17880
CY2023Q3 miro Lessee Finance And Operating Leases Liability Payments Due
LesseeFinanceAndOperatingLeasesLiabilityPaymentsDue
3198382
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
360786
CY2023Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
599
CY2023Q3 miro Lessee Finance And Operating Lease Liability Undiscounted Excess Amount
LesseeFinanceAndOperatingLeaseLiabilityUndiscountedExcessAmount
361385
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2819716
CY2023Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
17281
CY2023Q3 miro Finance And Operating Lease Liability
FinanceAndOperatingLeaseLiability
2836997
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y8M12D
CY2023Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P0Y9M18D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.042
CY2023Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.068
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4842282
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4713964
CY2023Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
0001558370-23-019009-index-headers.html Edgar Link pending
0001558370-23-019009-index.html Edgar Link pending
0001558370-23-019009.txt Edgar Link pending
0001558370-23-019009-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
miro-20230930.xsd Edgar Link pending
miro-20230930x10q.htm Edgar Link pending
miro-20230930xex31d1.htm Edgar Link pending
miro-20230930xex31d2.htm Edgar Link pending
miro-20230930xex32d1.htm Edgar Link pending
miro-20230930xex32d2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
miro-20230930_cal.xml Edgar Link unprocessable
miro-20230930_def.xml Edgar Link unprocessable
miro-20230930_lab.xml Edgar Link unprocessable
miro-20230930_pre.xml Edgar Link unprocessable
miro-20230930x10q_htm.xml Edgar Link completed
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable